Before you sell to, join or invest in Anebulo Pharmaceuticals, Inc.
MentionFox check on Anebulo Pharmaceuticals, Inc.: only 1 source on file so far (checked 6 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/anebulo-pharmaceuticals-inc-form-d-24000001
Check Anebulo Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
Anebulo Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2024-12-31.
Anebulo Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 31, 2024. The filing reports $15M sold. Its industry group is Pharmaceuticals. It names Richard Cunningham (Executive Officer, Director), Daniel George (Executive Officer), Joseph Lawler (Director) (SEC Form D, December 31, 2024).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Anebulo Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2024-12-31 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Anebulo Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Anebulo Pharmaceuticals, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Anebulo Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Anebulo Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Anebulo Pharmaceuticals, Inc. →Get the full cited report on Anebulo Pharmaceuticals, Inc.
What the filing shows about Anebulo Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anebulo Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Anebulo Pharmaceuticals, Inc.'s address as 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Anebulo Pharmaceuticals, Inc. See pricing
Anebulo Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1815974) and has filed since 2022-10-11. 2 filings are on record, the latest on 2024-12-31.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Anebulo Pharmaceuticals, Inc.'s Form D of 2024-12-31 names Richard Cunningham, Daniel George, Joseph Lawler and 6 more as its officers, directors or promoters.
Its new offerings report $21.65M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers
Richard Cunningham is named as Executive Officer and Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Daniel George is named as Executive Officer on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Joseph Lawler is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Aron English is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Kenneth Lin is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Areta Kupchyk is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Bimal Shah is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Jason Aryeh is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
Nathaniel Calloway is named as Director on the Form D that Anebulo Pharmaceuticals, Inc. filed with the SEC on 31 December 2024, one of 9 people that filing names.
9 people named on the filing — 2 holding an executive role and 7 as directors only.
Named as of the 2024-12-31 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Anebulo Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Anebulo Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Anebulo Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Anebulo Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Anebulo Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Anebulo Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/anebulo-pharmaceuticals-inc-form-d-24000001